Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Raptiva (efalizumab)-Important Safety Information from Merck Serono following approval by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
22/02/2009
Problem Or Issue:
Please find herewith an important healthcare professional communication from Merck Serono on the recommended suspension of the marketing authorisation for Raptiva.
Important Safety Information-Raptiva
(efalizumab)
« Back
Date Printed: 07/05/2024